An economic analysis of autologous hematopoietic stem cell transplantation (AHSCT) in the treatment of new onset type 1 diabetes

Acta Diabetologica
Emilian SnarskiWiesław Wiktor-Jedrzejczak

Abstract

Autologous hematopoietic stem cell transplantation (AHSCT) is an emerging treatment option in new onset type 1 diabetes (T1DM), leading to a remission of the T1DM for a longer time period in up to 50 % of patients. The aim of the study was to analyze the cost-effectiveness of this treatment option compared with standard insulin therapy. The medical records of patients who had undergone immunoablation with AHSCT for new onset T1DM were analyzed for the cost-effectiveness of the treatment using the IMS CORE Diabetes Model. The expected survival of patients with T1DM treated solely with insulin (without transplantation) was estimated to be 34.4 years, and their quality-adjusted survival was 13.8 QALY, whereas the expected survival of the patients treated with AHSCT was 34.9 years when the HbA1c benefit over standard treated patients lasted for 2, 35.4 years with 8-year benefit and even up to 40.3 years with the lifelong benefit scenario. Values under the threshold of ICER were reached after 8 years of sustained benefit in terms of HbA1c concentration. If discounting was not applied, the threshold values were reached after 3 years of HbA1c benefit over the standard group, independent of insulin use after transplantation. The result...Continue Reading

References

May 11, 1979·JAMA : the Journal of the American Medical Association·W B Kannel, D L McGee
Sep 30, 1993·The New England Journal of Medicine·UNKNOWN Diabetes Control and Complications Trial Research GroupC Siebert
Apr 12, 2007·JAMA : the Journal of the American Medical Association·Júlio C VoltarelliRichard K Burt
Sep 12, 2008·The New England Journal of Medicine·Rury R HolmanH Andrew W Neil
Dec 3, 2008·Diabetic Medicine : a Journal of the British Diabetic Association·M AndelUNKNOWN DEPAC Group
Apr 14, 2009·Population Health Management·Timothy M DallShiping Zhang
May 8, 2010·Clinical Immunology : the Official Journal of the Clinical Immunology Society·Roberto Francese, Paolo Fiorina
Aug 25, 2011·Endocrine Reviews·Paolo FiorinaNicholas Zavazava
Jun 16, 2012·Blood·Nandita KheraStephanie J Lee

❮ Previous
Next ❯

Citations

Jan 13, 2018·Journal of Crohn's & Colitis·John A SnowdenUNKNOWN Joint Accreditation Committee of the International Society for Cellular Therapy (ISCT) and EBMT (JACIE)
Jul 27, 2021·Frontiers in Immunology·Ida PastorePaolo Fiorina

❮ Previous
Next ❯

Related Concepts

Related Feeds

Blood And Marrow Transplantation

The use of hematopoietic stem cell transplantation or blood and marrow transplantation (bmt) is on the increase worldwide. BMT is used to replace damaged or destroyed bone marrow with healthy bone marrow stem cells. Here is the latest research on bone and marrow transplantation.